Drug intelligence / Profile preview

Bitonning

Development stage: Unknown
Lead developer: Sino Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Bitonning Capsule (痹通宁胶囊) is an oral traditional Chinese medicine (TCM) developed and manufactured by Guangzhou Zhengba Pharmaceutical (Hengba Pharma). It is officially approved in China (National Drug Approval No. Z20025071) for the treatment of arthralgia, specifically wind-cold-dampness Bi-syndrome, which includes conditions such as rheumatoid arthritis. The formulation contains a blend of processed Strychni Semen (马钱子粉), Ephedra (麻黄), Atractylodes (苍术), Dioscorea nipponica (穿山龙), Scorpio (全蝎), Bombyx batryticatus (僵蚕), and Glycyrrhiza (甘草). Its therapeutic actions focus on dispelling wind, eliminating dampness, reducing swelling, and alleviating pain associated with chronic joint inflammation.

Brand names: Bitonning痹通宁
Other names: Bitonning CapsuleBitonning Jiaonang痹通宁胶囊

Beyond the preview

Go deeper on Bitonning.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bitonning.

Explore the full profile